Skip to content

Pipeline

Product Indication Industry Partners Status
Unit Dose GANFORT™ (EU) Glaucoma
- Filed
Alpha II Agonist - NCE Glaucoma
- Pre-Clinical
Bimatoprost Sustained Release Glaucoma
- Phase 2
OZURDEX® Diabetic Macular Edema
- Phase 3
RESTASIS® (EU) Ocular Surface Disease
- Phase 3
RESTASIS® X Ocular Surface Disease
- Phase 2
NOVADUR® (Brimonidine) Retinal Diseases
- Phase 2
AGN 208397 Retinal Diseases
- Phase 2
AGN 150998 (Anti-VEGF DARPin®) Age-Related Macular Degeneration
- Phase 2
Anti-VEGF/PDGF-B DARPin® Age-Related Macular Degeneration
- Pre-Clinical
TKI Age-Related Macular Degeneration
- Pre-Clinical
Product Indication Industry Partners Status
LEVADEX® Migraine - Acute Therapy
MAP Pharmaceuticals, Inc. Filed
BOTOX® Juvenile Cerebral Palsy
- Phase 3
TEM Pain
- Phase 2
BOTOX® Osteoarthritis Pain
- Phase 2
Product Indication Industry Partners Status
SER-120 Nocturia
Serenity Pharmaceuticals, LLC Phase 3
Product Indication Industry Partners Status
BOTOX® Cosmetic (U.S. & EU) Crows Feet Lines
- Filed
LATISSE® (EU National Agencies) Lash
- Phase 3
LATISSE® Brow
- Phase 2
Bimatoprost Scalp
- Phase 2
Oxymetazoline (Vicept V-101) Rosacea
- Phase 2
Product Indication Industry Partners Status
JUVÉDERM® VOLUMA™ (U.S.) Facial Aesthetics
- Filed
JUVÉDERM® Volbella™ (U.S.) Facial Aesthetics
- Feasibility
JUVÉDERM® Volift™ (U.S.) Facial Aesthetics
- Feasibility